Drug Trial Radar · NCT02060383
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
Last checked: Nov 20, 2026Latest source record: May 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
249
Actual
Start
May 23, 2014
Primary completion
Feb 5, 2018
Study completion Mar 26, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 12, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin. This was a Phase IV, multi-center, randomized, open-label study. Eligible patients started pasireotide subcutaneously (s.c.) for Cushing's disease and pasireotide LAR (long-acting release) for Acromegaly. Participants being treated with pasireotide s.c or LAR at screening were eligible as long as they met protocol criteria during the screening period. If previously normo-glycemic participants experienced an increase in their fasting blood glucose and met the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to have elevated blood glucose above target on metformin within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Participants who continued to receive clinical benefit after completing the Core Phase could enter an optional Extension Phase if pasireotide was not commercially available in their country or a local access program was not available to provide drug. Patients continued in the Extension Phase until the last participant randomized in the Core Phase completed 16 weeks of treatment post-randomization.
Conditions
- Cushing's Disease
- Acromegaly
Interventions
Pasireotide s.c.Drug
Administered to Cushing's disease participants.
SitagliptinDrug
Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective
LiraglutideDrug
Participant switched to liraglutide if sitagliptin was found not to be effective.
InsulinDrug
Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required. Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator. Note: OAD and No OAD groups within the non-randomized arm did not take Insulin.
Pasireotide LARDrug
Administered to Acromegaly participants.
MetforminDrug
If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator. Note: No OAD group within the non-randomized arm did not take metformin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c From Randomization to Approximately 16 WeeksTime frame: Randomization, 16 weeks
Locations
43 sites in 12 countries. Site status is shown where the registry gives one.
Diabetes and Endocrine Associates La Mesa Location
Multiple Locations, California
LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219
Torrance, California
Coastal Metabolic Research Centre SC
Ventura, California
East Coast Institute for Research East Coast Inst. for Res(ECIR)
Jacksonville, Florida
Washington University SC - SOM230B2411
St Louis, Missouri
Great Falls Clinic
Great Falls, Montana
Robert Wood Johnson Medical School - Rutgers SC
New Brunswick, New Jersey
The Mount Sinai Hospital SC
New York, New York
Columbia University Medical Center New York Presbyterian Neuroendocrine Unit
New York, New York
Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC
New York, New York
Allegheny Endocrinology Associates SC
Pittsburgh, Pennsylvania
Vanderbilt Clinical Trials Center SOM230B2219
Nashville, Tennessee
Baylor College of Medicine Ben Taub General Hosp.
Houston, Texas
Virginia Endocrinology Research SC-2
Chesapeake, Virginia
Swedish Medical Center Dept.ofSeattle Neuroscience(2)
Seattle, Washington
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Wilrijk, Belgium
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Joinville, Santa Catarina, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Beijing, Beijing Municipality, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Chengdu, Sichuan, China
Novartis Investigative Site
Aalborg, Denmark
Novartis Investigative Site
Aarhus, Denmark
Novartis Investigative Site
Herlev, Denmark
Novartis Investigative Site
Odense C, Denmark
Novartis Investigative Site
Erlangen, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Oldenburg, Germany
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Vellore, Tamil Nadu, India
Novartis Investigative Site
San Isidro, Lima region, Peru
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Wroclaw, Poland
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Bangkok, Thailand
Novartis Investigative Site
Bangkok, Thailand
Novartis Investigative Site
Songkhla, Thailand
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.